Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Stocks Rise Ahead of Inflation Data, Earnings, Fed Meeting
Stocks rose at the opening bell as the market awaits updates on inflation data while earnings kick off this week for the second quarter. The Federal Reserve is also slated to meet later this month as investors anxiously await its decision on rates.
Load More